The number of digital medicine technologies, a category of tools that use software and algorithmically driven products to measure or intervene to improve human health, [1] has expanded enormously in recent years, further accelerated by the need for remote care delivery during the COVID-19 pandemic, and now ranges from telemedicine to serious gaming, wearable devices, AI-supported diagnostics, and clinical decision support systems (CDSSs), among others. Building on the experiences during the pandemic, there is a real potential for the digital transformation of health care to the benefit of patients worldwide. However, the promising developments to date are at risk of stalling due to inherent limitations in the way digital medicine and especially medical artificial intelligence (AI) technologies are being developed and implemented today. [2] Already in 2017, the number of digital medicine technologies on the worldwide market exceeded 318 000, with the mobile application segment growing by over 200 daily. [3] There are widespread expectations that the surge will lead to improvement of health care globally, [4] not least evidenced by the WHO declaration on digital health, [5] and by the rapid growth of private and public investment in this field. [6,7] The advent of digital medicine bears special promise for low-and middleincome countries (LMIC), where applications such as telemedicine and CDSS may enable these countries to "leapfrog" from today's often insufficient healthcare systems into more efficient, accessible, and patient-centric models, [8] similar to what has been seen in Africa's finance sector. [9] The level of improvement possible would correspond to the digital transformation seen in other sectors of society, such as media and retail industries, with the digitalization of processes and service models, beyond the mere digitization of traditional healthcare practices seen so

No abstract